Search | Clinical Trials Finder

Conditions: Obesity
Interventions: CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more

Conditions: Autistic Disorder
Interventions: methylcobalamin, saline placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years to 8 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Oleclumab, Monalizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,051 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 33
States / cities: San Diego, California • New Haven, Connecticut • Stuart, Florida + 28 more

Conditions: Androgenic Alopecia
Interventions: Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer
Interventions: Anastrozole, AZD0530 (saracatinib), Placebo; Drug
Lead sponsor: Joyce Marie Slingerland, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Palo Alto, California • Miami, Florida

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Liver Fibrosis/NASH
Interventions: BMS-986171, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Chula Vista, California • Cypress, California

Conditions: Prostate Cancer
Interventions: Nivolumab, Prednisone, Docetaxel, Placebo; Biological · Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 45
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 41 more

Conditions: Alzheimer Disease
Interventions: Citicoline supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Acne
Interventions: Acne mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more

Conditions: Rheumatoid Arthritis
Interventions: Lutikizumab, Placebo, Ravagalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 56
States / cities: Peoria, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 48 more

Conditions: Acute Coronary Syndrome
Interventions: Placebo, St. Johns Wort; Drug
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Covid19
Interventions: Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more

Conditions: Cytomegalovirus Infections
Interventions: MF-59, Placebo, CMV gB vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Cincinnati, Ohio • Nashville, Tennessee • Galveston, Texas + 1 more

Conditions: Alzheimer's Disease
Interventions: MK-1167, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Hallandale, Florida • Decatur, Georgia • Savannah, Georgia

Conditions: Hemorrhagic Shock, Trauma Injury
Interventions: Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT); Biological · Drug
Lead sponsor: Philip Spinella; Other
Eligibility: Up to 17 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Ulcerative Colitis (UC)
Interventions: XmAb942, Placebo; Biological · Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 29
States / cities: Scottsdale, Arizona • Bradenton, Florida • Brandon, Florida + 24 more

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Interventions: ABT-751, Placebo, Docetaxel; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Burbank, California • Orange, California + 10 more

Conditions: Chemotherapy-induced Diarrhea
Interventions: SK10, Placebo; Drug
Lead sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Progressive Supranuclear Palsy
Interventions: TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 41 Years to 86 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more

Search by objective public record fields.

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Improving Sleep and Cognition in Alzheimer's Disease

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)